Although significant progress has been made in modeling glycosylation at small scales, scaling up to production bioreactors introduces complex gradients in nutrients, oxygen, pH, and metabolite concentrations that affect cellular performance, ultimately impacting product properties including glycosylation. This project addresses a critical need in upstream bioprocess modeling: predicting the impact of hydrodynamic heterogeneity on glycosylation outcomes during CHO based protein production for different scales and bioreactor configurations.
This proposal brings together researchers in mammalian hydrodynamics and systems biology of glycosylation to deliver an interoperable simulation platform integrating spatially resolved CFD flow fields, cell kinetics, and mechanistic models of intracellular glycosylation. The platform will help NIIMBL partners build digital twins, accelerate process development, validate glycosylation robustness, and inform scale-up decisions. This platform can be extended in the future to include automated CFD routines and machine learning-assisted parameter optimization. The tool will support both research and industrial applications, advancing NIIMBL’s mission to accelerate biomanufacturing innovation.
The platform will help NIIMBL partners build digital twins, accelerate process development, validate glycosylation robustness, and inform scale-up decisions.
This platform can be extended in the future to include automated CFD routines and machine learning-assisted parameter optimization. The tool will support both research and industrial applications, advancing NIIMBL’s mission to accelerate biomanufacturing innovation.
This project seeks to demonstrate a computational bioreactor modeling platform that improves scale-up predictions for drug companies, resulting in quality benefits across large-scale manufacturing.
Deliverables include Python software packages, step-by-step example workflows, training materials, and graphical output of key metrics (e.g., glycan distribution over time, pH and oxygen maps).
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

The Ohio State University
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
EMD Millipore Corporation
Federal Stakeholder: National Institute of Standards and Technology
Johns Hopkins University
Pfizer, Inc.
Sanofi